Regeneron, Sanofi announce Dupixent outperformed Xolair
Confident Investing Starts Here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
9 hours ago
- Forbes
The Three Categories Of AI Driving a Pharma Revolution
| Aug 14, 2025, 11:29PM EDT Sanofi's Chief Digital Officer Emmanuel Frenehard had a thought that he just couldn't shake: how can Sanofi extend the lifespan for patients around the world? To solve the problem, Frenehard implemented AI in three categories in a concentrated effort across the company.
Yahoo
19 hours ago
- Yahoo
US eosinophilic oesophagitis market to reach $1.19bn by 2030
The eosinophilic oesophagitis (EoE) market in the US is forecast to grow from $202 million in 2020 to $1.19 billion in 2030, representing a robust compound annual growth rate of 19.4%, according to GlobalData. This growth will be fueled by the shift from off-label treatments such as proton pump inhibitors and compounded topical corticosteroids, towards more patient-friendly, US Food and Drug Association-approved therapies such as Sanofi/Regeneron's Dupixent (dupilumab), Takeda's Eohilia (budesonide oral suspension and Ellodi Pharmaceuticals' late-stage pipeline agent, APT-1011, an orally disintegrating tablet (ODT). Dupixent, first approved for EoE in adults and adolescents in 2022 then expanded in 2024 to treat children as young as one, has quickly established itself as a first-line biologic due to its strong efficacy, favourable safety profile and biweekly subcutaneous administration. Takeda's Eohilia, approved in 2024 as the first oral, targeted steroid for EoE, is expected to capture significant market share thanks to its ease of use compared to swallowed inhaler steroids. The anticipated launch of APT-1011, an ODT formulation of fluticasone propionate, will add further choice for patients, particularly in paediatrics where dosage form is a major factor in adherence. By 2030, Dupixent and Eohilia are expected to account for 75% of the US EoE market, with APT-1011 contributing 12.5%. The late-stage pipeline remains active, with more than 100 interventional trials initiated as of 2025, including novel biologics such as Amgen and AstraZeneca's co-developed Tezspire (tezepelumab), which targets upstream thymic stromal lymphopoietin (TSLP) signalling and next-generation corticosteroid formulations. Key opinion leaders interviewed by GlobalData noted a shift in clinical trial design toward multidomain endpoints that integrate histologic, endoscopic and patient-reported outcomes, moving beyond the traditional histologic remission threshold of 15 eosinophils or fewer per high-power field. This evolution reflects payer demand for more comprehensive measures of clinical benefit, particularly sustained improvement in swallowing function and quality of life. Despite the strong growth outlook, the market faces challenges. Payer step therapy and restrictive coverage criteria may limit broad adoption of biologics, while high list prices, such as Eohilia's reported launch price at approximately $5,250, could hinder uptake without robust cost-effectiveness data. Reliance on invasive endoscopy for diagnosis and monitoring also remains a significant burden, particularly in paediatric populations, though emerging tools such as the oesophageal string test and cytosponge could reduce procedure frequency. With multiple novel therapies expected to launch and the treatment paradigm shifting toward earlier, targeted intervention, GlobalData anticipates that the US EoE market will undergo rapid expansion over the forecast period, offering substantial opportunities for both biologic and small-molecule developers targeting this historically underserved condition. "US eosinophilic oesophagitis market to reach $1.19bn by 2030" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
a day ago
- Yahoo
After Decades of Mysterious Pain, I Finally Got the Diagnosis That Changed My Life
I have a busy and fulfilling life: I teach writing classes, I mentor a young girl, and I volunteer at my local history museum. I also have great group of supportive friends. But it wasn't always this way. I have struggled with chronic pain almost my entire life. The first time I recall feeling pain, I was three years old. My bones felt like they were being crushed at night, and I screamed in agony. Mystified, my parents took me to many doctors, including more than a dozen specialists. The diagnosis? Hypersensitivity to pain, and hyperallergic to everything. They told my parents give me Benadryl when I had a painful 'allergy attack,' as they called it. Bu it was so much more than that. Growing up in pain By age nine, I had daily headaches. Benadryl and Tylenol barely worked. I couldn't play outside with my friends because I got painful welts from the sun. My hip and arm joints ached constantly. A growth spurt at ten triggered more screaming episodes, so we went back to more doctors. Again, no answers. My parents believed me, but by twelve, we still had no diagnosis, and I had shingles–twice. The doctor didn't do any tests. He dismissed me with, 'You're the most stressed-out seventh grader I've ever met. Your problems aren't that bad.' I felt defective and terribly alone. After jumping over hurdles in P.E. class popped my knees out of the socket, I saw an orthopedist who handed me an Ace bandage and told me I'd 'grow into my joints.' I never did, and that bandage became my companion throughout high school. College was not an option for me–financially or physically. Crossing campus would hurt. So I began working, managing nonprofits, but the cycle repeated: work, get sick, lose my job, start over. It curtailed my career, and my dreams of travel became early flights home and canceled plans. My body revolted. By my thirties, my symptoms included electric nerve shocks, severe neuropathy, tremors, and agonizing spasms. Sitting made my legs painfully numb. I was desperate, until a relative suggested I try the Mayo Clinic, which is local to me in Arizona. The doctors there were shocked at my thin frame and gaunt gaze. I saw over fifteen specialists there, because every system in my body was involved. The doctors suspected I had an autoimmune disease, but my case was so complex they couldn't pinpoint a cause. At thirty-two, I started experiencing intense stomach cramps, vomiting, and joint pain. Since I had no official diagnosis, there was no recommended treatment, and no one would prescribe pain medicine without a diagnosis. Turning a corner My mom moved in to care for me, and with her gentle presence, she gave me a renewed sense of hope. I had the courage to keep going. Her unconditional love and unwavering support propped me up. Another helpful moment was when my doctors suggested I try medical cannabis. Within a week, the stomach pain eased, but I still experienced joint and nerve pain. At that point, a doctor finally prescribed pain medication, which brought some relief. I also returned to childhood coping tools. Growing up in a New Age household, I used meditation and biofeedback (visualization of the pain leaving). They don't erase the pain, but they do allow me to take a mental step back from it. Then, things changed when, after all those years, I finally had a name for my condition: The doctors at Mayo discovered I had mast cell activation syndrome (MCAS), and afterward, they diagnosed me with multiple chronic conditions, including chronic inflammatory demyelinating polyneuropathy (CIDP), small fiber neuropathy (SFN), piriformis syndrome, and hypermobility Ehlers-Danlos syndrome (hEDS) MCAS explained so much. It's a condition in which mast cells—the body's first responders—go haywire and release floods of inflammatory chemicals. It worsens everything else, including my nerve and joint pain. Finally getting diagnosed and knowing what was happening in my body was life changing. It wasn't just a diagnosis, it was validation. I had been treated like a mystery to solve or problem to dismiss. Now doctors came to me with solutions and a treatment plan. Most importantly, it renewed my sense of hope. I could begin to heal. Moving forward with hope In 2022, after losing my mom and close family members, I needed connection. I wanted to help people who are suffering silently. I co-founded The Chronic Haven, a nonprofit peer support group for people living with chronic illness and pain. We offer online support meetings, game nights, creative classes, and more. This is where I found my tribe, and it brings me so much joy. Finally, at 45, I was approved for intravenous immunoglobulin immunotherapy (IVIG) for CIDP/SFN. Every two weeks, I receive donor antibodies that help rebuild the myelin sheaths around my nerves. It's helping immensely. I have much to live for today. I have a better quality of life. I look forward to IVIG days, because that means I am one step close to being better. I am happy today, with supportive friends and a good team of doctors in place. I have found my smile again. You Might Also Like Can Apple Cider Vinegar Lead to Weight Loss? Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
